N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
N/A N=229 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Covid19
Primary: Number of Infected Subjects — 0; 11 Participants — p=< 0.0001
Phase 2 N=217 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
Phase 4 N=44 Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
Diarrhea · COVID-19
Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
N/A N=10 Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
Phase 4 N=50 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
Increased Risk of SARS-CoV-2 Infection
Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants
N/A N=246 Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada
SARS-CoV-2 · Covid19 · Corona Virus Infection
Primary: Rate of Perinatal Transmission of SARS-CoV-2 — 12.3 percentage of participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
Phase 2 N=98 COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
COVID-19 · SARS-CoV 2
Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
N/A N=15 Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)
Coronavirus
Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated
N/A N=881 Understanding COVID-19 Infection in Pregnant Women and Their Babies
Corona Virus Infection · Pregnancy Related · Neonatal Infection
Primary: Antibody Concentrations in Maternal Blood in Pregnant Women in England — 37.2; 7.2; 80.3; 590.5 CAU/ml
N/A N=1,114 COVID-19 Antibody and Reinfection Study
COVID-19 Testing
Primary: Reinfection With SARS-CoV-2 — 12; 77; 68; 957 Participants
N/A N=214 Symptom-Based Markers for COVID-19 Transmission
Covid19
Primary: Body Temperature — 98.1 degrees Fahrenheit
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
Phase 4 N=659 BCG Vaccine for Health Care Workers as Defense Against COVID 19
Coronavirus · Coronavirus Infection · Coronavirus as the Cause of Diseases Classified Elsewhere
Primary: Number of New COVID 19 Infections — 25; 21 Participants
N/A N=45 A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
COVID-19 · Influenza
Primary: Positive Percent Agreement — 52 percent of nasal swabs
N/A N=100 APT™ T3X on the COVID-19 Contamination Rate
COVID-19
Primary: COVID-19 Contamination Rate. — 2; 5 Participants
Phase 1 N=150 N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Coronavirus · Covid19
Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
N/A N=9 Use of Continuous Glucose Monitors in Coronavirus Disease 2019 ICU and Potential Inpatient Settings
Covid19 · Diabetes Mellitus
Primary: Time in Range — 21.6 percentage of time
N/A N=614 SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
SARS-CoV-2 Infection · Influenza A · Influenza B
Primary: Qualitative Detection of RNA From SARS-CoV-2, Influenza A, and Influenza B ; Positive Percent Agreement Performance Comparison of Candidate Device (Metrix) vs…
N/A N=48 Cohort Isolation and Cross-infection in Bronchiolitis
Bronchiolitis
Primary: Duration of Hospital Stay — 3.9; 2.1 days